NCT06130592 Technical Feasibility Study of Ultrasound Muscle Imaging in Antenatal Ultrasound
| NCT ID | NCT06130592 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Grenoble |
| Condition | Arthrogryposis Multiplex Congenita (AMC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 230 participants |
| Start Date | 2024-05-12 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 230 participants in total. It began in 2024-05-12 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the study is to evaluate the performance of muscle ultrasound sections on antenatal ultrasound between 21-24 amenorrhea weeks for the screening of muscle atrophy, in a sample of low-risk and high-risk pregnancies of congenital multiple arthrogryposis
Eligibility Criteria
Inclusion Criteria: * Any pregnant woman consulting in one of the two obstetric gynecology departments in connection with the CPDPN (Multidisciplinary Prenatal Diagnostic Centers) of the University hospitals of Lyon or Grenoble. * Mono-embryonic pregnancy. * Gestational ages retained on the first dating ultrasound or the 1st trimester ultrasound between 21-24 amenorrhea weeks. * For women at "high risk": diagnosis during ultrasound of the 1st, 2nd, or 3rd trimesters, of an abnormality of position / deformation of one or more joints, and / or an abnormality of fetal movements on screening ultrasound or interrogation (population group at "high risk of AMC"). * Regulatory criteria: adults, affiliated to a social security scheme, having signed a consent Exclusion Criteria: * Multiple pregnancies, and / or non-progressive . * Obese women (BMI \> 30 in early pregnancy) * Subject in a period of exclusion from another study * Subject under administrative or judicial supervision * Subject who cannot be contacted in case of emergency
Contact & Investigator
Klaus DIETERICH, MD,PhD
PRINCIPAL INVESTIGATOR
Univ. Grenoble Alpes Inserm U1209 IAB CHU Grenoble Alpes
Frequently Asked Questions
Who can join the NCT06130592 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 55 Years, studying Arthrogryposis Multiplex Congenita (AMC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06130592 currently recruiting?
Yes, NCT06130592 is actively recruiting participants. Contact the research team at lpejot@chu-grenoble.fr for enrollment information.
Where is the NCT06130592 trial being conducted?
This trial is being conducted at La Tronche, France, Bron, France.
Who is sponsoring the NCT06130592 clinical trial?
NCT06130592 is sponsored by University Hospital, Grenoble. The principal investigator is Klaus DIETERICH, MD,PhD at Univ. Grenoble Alpes Inserm U1209 IAB CHU Grenoble Alpes. The trial plans to enroll 230 participants.